212Pb labelled mAbs targeting the epidermal growth factor receptor (EGFR a.k.a. HER1), cluster of differentiation 146 (CD146) and protein tyrosine kinase 7 (PTK7) have been investigated preclinically for colorectal cancer, mesothelioma, and ovarian cancer respectively (Lindland et al. 2024a; Lindland et al. 2024b; Milenic et al. 2015a; Milenic et al. 2017). This evidence concerns the gene EGFR and ovarian cancer.